Hamid Moradi1,2, Christina Park3, Elani Streja3,4, Donovan A Argueta5, Nicholas V DiPatrizio5, Amy S You3, Connie M Rhee3, Nosratola D Vaziri3, Kamyar Kalantar-Zadeh3,4, Daniele Piomelli6. 1. Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA, hmoradi@uci.edu. 2. Tibor Rubin VA Medical Center, Nephrology Section, Long Beach, California, USA, hmoradi@uci.edu. 3. Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA. 4. Tibor Rubin VA Medical Center, Nephrology Section, Long Beach, California, USA. 5. Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA. 6. Anatomy and Neurobiology, University of California Irvine School of Medicine, Irvine, California, USA.
Abstract
BACKGROUND: Mortality in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (MHD) remains exceptionally high. While traditional risk factors such as obesity are paradoxically associated with better survival, nontraditional risk factors including cachexia increase the likelihood of poor outcomes. There is accumulating evidence that the endocannabinoid (ECB) system plays a major role in energy preservation and storage, factors which can prevent the deleterious effects of cachexia. Hence, in this study, we evaluated the association of circulating ECB levels with mortality in MHD patients. METHODS: Serum concentrations of anandamide (AEA) and 2-arachidonoyl-sn-glycerol (2-AG), major ECB ligands, were measured in MHD patients. Their correlation with various clinical/laboratory indices and association with 12-month all-cause mortality were examined. RESULTS: Serum 2-AG levels positively correlated with body mass index, serum triglycerides and body anthropometric measures. Meanwhile, serum AEA levels correlated positively with serum interleukin-6, and negatively with serum very low-density lipoprotein levels. While increased serum 2-AG levels were associated with reduced risk of all-cause mortality (hazard ratio [HR] 0.52, 95% CI 0.28-0.98), there was no clear association between serum AEA levels and mortality (HR 0.91, 95% CI 0.48-1.72). CONCLUSIONS: In MHD patients, the circulating levels of ECB ligand, 2-AG, may play an important role in determining body mass and risk of mortality. These observations were unique to 2-AG as similar findings were not obtained with serum AEA. Future studies need to investigate the mechanisms responsible for these associations and examine the modulation of the ECB system as a potential target for therapy in ESRD.
BACKGROUND:Mortality in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (MHD) remains exceptionally high. While traditional risk factors such as obesity are paradoxically associated with better survival, nontraditional risk factors including cachexia increase the likelihood of poor outcomes. There is accumulating evidence that the endocannabinoid (ECB) system plays a major role in energy preservation and storage, factors which can prevent the deleterious effects of cachexia. Hence, in this study, we evaluated the association of circulating ECB levels with mortality in MHD patients. METHODS: Serum concentrations of anandamide (AEA) and 2-arachidonoyl-sn-glycerol (2-AG), major ECB ligands, were measured in MHD patients. Their correlation with various clinical/laboratory indices and association with 12-month all-cause mortality were examined. RESULTS: Serum 2-AG levels positively correlated with body mass index, serum triglycerides and body anthropometric measures. Meanwhile, serum AEA levels correlated positively with serum interleukin-6, and negatively with serum very low-density lipoprotein levels. While increased serum 2-AG levels were associated with reduced risk of all-cause mortality (hazard ratio [HR] 0.52, 95% CI 0.28-0.98), there was no clear association between serum AEA levels and mortality (HR 0.91, 95% CI 0.48-1.72). CONCLUSIONS: In MHD patients, the circulating levels of ECB ligand, 2-AG, may play an important role in determining body mass and risk of mortality. These observations were unique to 2-AG as similar findings were not obtained with serum AEA. Future studies need to investigate the mechanisms responsible for these associations and examine the modulation of the ECB system as a potential target for therapy in ESRD.
Authors: Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Rajiv Saran; Bruce Robinson; Kevin C Abbott; Lawrence Y C Agodoa; Jennifer Bragg-Gresham; Rajesh Balkrishnan; Nicole Bhave; Xue Dietrich; Zhechen Ding; Paul W Eggers; Abduzhappar Gaipov; Daniel Gillen; Debbie Gipson; Haoyu Gu; Paula Guro; Diana Haggerty; Yun Han; Kevin He; William Herman; Michael Heung; Richard A Hirth; Jui-Ting Hsiung; David Hutton; Aya Inoue; Steven J Jacobsen; Yan Jin; Kamyar Kalantar-Zadeh; Alissa Kapke; Carola-Ellen Kleine; Csaba P Kovesdy; William Krueter; Vivian Kurtz; Yiting Li; Sai Liu; Maria V Marroquin; Keith McCullough; Miklos Z Molnar; Zubin Modi; Maria Montez-Rath; Hamid Moradi; Hal Morgenstern; Purna Mukhopadhyay; Brahmajee Nallamothu; Danh V Nguyen; Keith C Norris; Ann M O'Hare; Yoshitsugu Obi; Christina Park; Jeffrey Pearson; Ronald Pisoni; Praveen K Potukuchi; Kaitlyn Repeck; Connie M Rhee; Douglas E Schaubel; Jillian Schrager; David T Selewski; Ruth Shamraj; Sally F Shaw; Jiaxiao M Shi; Monica Shieu; John J Sim; Melissa Soohoo; Diane Steffick; Elani Streja; Keiichi Sumida; Manjula Kurella Tamura; Anca Tilea; Megan Turf; Dongyu Wang; Wenjing Weng; Kenneth J Woodside; April Wyncott; Jie Xiang; Xin Xin; Maggie Yin; Amy S You; Xiaosong Zhang; Hui Zhou; Vahakn Shahinian Journal: Am J Kidney Dis Date: 2019-02-21 Impact factor: 8.860
Authors: Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer Journal: Trends Pharmacol Sci Date: 2015-03-18 Impact factor: 14.819
Authors: Morgan E Grams; Yingying Sang; Shoshana H Ballew; Juan Jesus Carrero; Ognjenka Djurdjev; Hiddo J L Heerspink; Kevin Ho; Sadayoshi Ito; Angharad Marks; David Naimark; Danielle M Nash; Sankar D Navaneethan; Mark Sarnak; Benedicte Stengel; Frank L J Visseren; Angela Yee-Moon Wang; Anna Köttgen; Andrew S Levey; Mark Woodward; Kai-Uwe Eckardt; Brenda Hemmelgarn; Josef Coresh Journal: Kidney Int Date: 2018-03-29 Impact factor: 18.998
Authors: Francheska Delgado-Peraza; Kwang H Ahn; Carlos Nogueras-Ortiz; Imran N Mungrue; Ken Mackie; Debra A Kendall; Guillermo A Yudowski Journal: Mol Pharmacol Date: 2016-03-23 Impact factor: 4.436
Authors: Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter Journal: Am J Nephrol Date: 2022-03-09 Impact factor: 4.605
Authors: Alex Y Pai; Cachet Wenziger; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli; Hamid Moradi Journal: Am J Nephrol Date: 2021-02-18 Impact factor: 3.754
Authors: Bruce A Watkins; Allon N Friedman; Jeffrey Kim; Kamil Borkowski; Shaun Kaiser; Oliver Fiehn; John W Newman Journal: Int J Mol Sci Date: 2022-08-29 Impact factor: 6.208
Authors: Elena V Kozlova; Bhuvaneswari D Chinthirla; Pedro A Pérez; Nicholas V DiPatrizio; Donovan A Argueta; Allison L Phillips; Heather M Stapleton; Gwendolyn M González; Julia M Krum; Valeria Carrillo; Anthony E Bishay; Karthik R Basappa; Margarita C Currás-Collazo Journal: Sci Rep Date: 2020-10-22 Impact factor: 4.379